Welcome to our dedicated page for Revelation Biosciences news (Ticker: $REVB), a resource for investors and traders seeking the latest updates and insights on Revelation Biosciences stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Revelation Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Revelation Biosciences's position in the market.
Revelation Biosciences, Inc. (NASDAQ: REVB) announced its financial results for the three months ended March 31, 2024. The company reported $14.6 million in cash and cash equivalents, up from $12.0 million in December 2023. They stated that the current cash is enough to fund operations through 2024. However, they reported a net loss of $2.7 million for the quarter, with significant expenses related to GEM-AKI and GEM-SSI clinical studies impacting their financials.